PM1 (Moderate) is met: variant c.1330C>T (p.Arg444Trp) is located in exon 11, a VCEP-designated critical functional domain for BRAF per RASopathy VCEP v2.3.0.¹ PP2 (Supporting) is met: BRAF gnomAD missense Z-score exceeds 3.09, indicating strong purifying selection against missense variation, consistent with a gene where missense variants are a common mechanism of RASopathy disease.² PM2 is not met: the variant is present in gnomAD v2.1 (1/251,378) and v4.1 (1/1,613,628), which precludes application under the VCEP rule requiring absence from controls.³ PP3 is not met: REVEL score (0.637) falls below the VCEP PP3 threshold of ≥0.7, and SpliceAI (max delta 0.09) predicts no splicing impact.⁴ No benign criteria are met. BA1 and BS1 are not met (allele frequency far below population thresholds). BP4 is not met (REVEL 0.637 > 0.3 threshold).⁵ Under RASopathy VCEP v2.3.0 combination rules, PM1_Moderate + PP2_Supporting does not satisfy any Pathogenic, Likely Pathogenic, Benign, or Likely Benign rule. The minimum for Likely Pathogenic requires either 1 Strong + 1 Moderate, or ≥3 Moderate, or 1 Moderate + ≥4 Supporting criteria. Final classification: Variant of Uncertain Significance (VUS).⁶ PVS1, PS5, PP4, PP5, BS3, BP6 are not applicable under the VCEP framework. PS1, PS2, PS3, PS4, PM5, PM6, PP1, BS2, BS4, BP2, BP5 are not assessed due to absence of data. PM2, PP3, BA1, BS1, BP1, BP4, BP7 were assessed and not met.⁷ Three ClinVar-attached PMIDs (25394175, 31829902, 35924163) were reviewed in full text; none mention NM_004333.5:c.1330C>T or p.Arg444Trp. These papers are clinical practice guidelines or consensus statements on cancer genetics referral and prostate cancer biomarkers and do not provide variant-specific evidence.⁸